Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia

Salome Funes,Jonathan Jung,Del Hayden Gadd,Michelle Mosqueda,Jianjun Zhong,Shankaracharya,Matthew Unger,Karly Stallworth,Debra Cameron,Melissa S. Rotunno,Pepper Dawes,Megan Fowler-Magaw,Pamela J. Keagle,Justin A. McDonough,Sivakumar Boopathy,Miguel Sena-Esteves,Jeffrey A. Nickerson,Cathleen Lutz,William C. Skarnes,Elaine T. Lim,Dorothy P. Schafer,Francesca Massi,John E. Landers,Daryl A. Bosco
DOI: https://doi.org/10.1038/s41467-024-46695-w
IF: 16.6
2024-03-20
Nature Communications
Abstract:Abstract Microglia play a pivotal role in neurodegenerative disease pathogenesis, but the mechanisms underlying microglia dysfunction and toxicity remain to be elucidated. To investigate the effect of neurodegenerative disease-linked genes on the intrinsic properties of microglia, we studied microglia-like cells derived from human induced pluripotent stem cells (iPSCs), termed iMGs, harboring mutations in profilin-1 (PFN1) that are causative for amyotrophic lateral sclerosis (ALS). ALS-PFN1 iMGs exhibited evidence of lipid dysmetabolism, autophagy dysregulation and deficient phagocytosis, a canonical microglia function. Mutant PFN1 also displayed enhanced binding affinity for PI3P, a critical signaling molecule involved in autophagic and endocytic processing. Our cumulative data implicate a gain-of-toxic function for mutant PFN1 within the autophagic and endo-lysosomal pathways, as administration of rapamycin rescued phagocytic dysfunction in ALS-PFN1 iMGs. These outcomes demonstrate the utility of iMGs for neurodegenerative disease research and implicate microglial vesicular degradation pathways in the pathogenesis of these disorders.
multidisciplinary sciences
What problem does this paper attempt to address?